Stocks · News reference
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Aclaris Therapeutics announced that CEO Dr. Neal Walker will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10, 2026. The clinical-stage biopharmaceutical company, which focuses on developing treatments for immuno-inflammatory diseases, will provide a live and archived webcast of the event on its website.
U.S. stock futures rise, Nasdaq 100 gains 200 points. Vipshop shares fall 4.9% after reporting Q2 earnings below expectations. Other stocks dip in pre-market trading.
A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected.
U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo beat estimates but cut FY26 outlook; oil jumped 5%.
Argenx announced Phase 2 success for FB102 in celiac disease while halting its Phase 3 UNITY study in Sjögren's disease for futility.